Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antibacterial effect of cefixime].

C J Soussy1, M Meyran, J Duval

  • 1Service du Bactériologie, CHU Henri-Mondor, Créteil.

Presse Medicale (Paris, France : 1983)
|October 11, 1989
PubMed
Summary

Cefixime (CFM) is a potent, orally active cephalosporin effective against many Gram-negative and Gram-positive bacteria. Its activity is comparable to third-generation cephalosporins, though reduced against certain resistant strains.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perspectives of oncology residents on Master's Degree in Science (MSc) programs: a national descriptive study by the French Association of Residents in Oncology (AERIO).

ESMO open·2024
Same author

Farm-specific failure costs of production disorders in European organic dairy herds.

Preventive veterinary medicine·2019
Same author

Double Layer of a Gold Electrode Probed by AFM Force Measurements.

Langmuir : the ACS journal of surfaces and colloids·2016
Same author

Distribution and antimicrobial susceptibility of bacteria from adults with community-acquired pneumonia or complicated skin and soft tissue infections in France: the nationwide French PREMIUM study.

Diagnostic microbiology and infectious disease·2015
Same author

The effect of renal denervation on endothelial function and inflammatory markers in patients with resistant hypertension.

International journal of cardiology·2015
Same author

[Health Care Insurance in France: its impact on income distribution between age and social groups].

Revue d'epidemiologie et de sante publique·2013

Area of Science:

  • Pharmacology
  • Microbiology
  • Infectious Diseases

Background:

  • Cefixime (CFM) is a novel orally administered cephalosporin antibiotic.
  • It demonstrates significant affinity for penicillin-binding proteins (PBPs) 3, 1a, and 1bs.
  • CFM exhibits outer membrane penetration characteristics similar to third-generation cephalosporins.

Purpose of the Study:

  • To evaluate the in vitro antibacterial activity of Cefixime (CFM).
  • To assess CFM's efficacy against a broad spectrum of bacterial pathogens.
  • To compare CFM's activity with existing cephalosporins.

Main Methods:

  • Minimum Inhibitory Concentrations (MICs) were determined using the agar dilution method.
  • Testing was performed on 2,489 bacterial isolates from 10 different hospitals.
  • Susceptibility testing included various species of Enterobacteriaceae, Haemophilus, Neisseria, Moraxella, Staphylococcus, Enterococcus, Streptococcus, and Streptococcus pneumoniae.

Main Results:

  • CFM demonstrated potent activity against non-beta-lactamase-producing Enterobacteriaceae (e.g., E. coli, Salmonella) and Haemophilus species.
  • Activity was reduced against strains producing cephalosporinases or extended-spectrum beta-lactamases.
  • CFM was inactive against Pseudomonas aeruginosa and Acinetobacter baumannii but showed moderate activity against methicillin-susceptible Staphylococcus aureus.

Conclusions:

  • Cefixime (CFM) exhibits broad-spectrum bactericidal activity, positioning it favorably among orally active cephalosporins.
  • Its efficacy is comparable to third-generation cephalosporins, particularly against susceptible Gram-negative organisms.
  • CFM's effectiveness may be limited in infections caused by bacteria with specific beta-lactamase resistance mechanisms.

Related Experiment Videos